QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)

Sera Prognostics Stock Price, News & Analysis (NASDAQ:SERA)

$1.89
-0.10 (-5.03%)
(As of 11/29/2023 ET)
Compare
Today's Range
$1.85
$2.04
50-Day Range
$1.65
$2.40
52-Week Range
$1.10
$4.25
Volume
9,846 shs
Average Volume
395,323 shs
Market Capitalization
$59.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.75

Sera Prognostics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
45.5% Upside
$2.75 Price Target
Short Interest
Healthy
1.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.16) to ($0.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

458th out of 949 stocks

Medical Laboratories Industry

11th out of 22 stocks


SERA stock logo

About Sera Prognostics Stock (NASDAQ:SERA)

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

SERA Stock Price History

SERA Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Sera Prognostics Inc Class A SERA
Sera Prognostics: Q3 Earnings Insights
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Sera Prognostics (NASDAQ: SERA)
See More Headlines
Receive SERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sera Prognostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/27/2024

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SERA
Fax
N/A
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.75
High Stock Price Target
$2.75
Low Stock Price Target
$2.75
Potential Upside/Downside
+45.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-44,190,000.00
Net Margins
-11,534.24%
Pretax Margin
-11,534.24%

Debt

Sales & Book Value

Annual Sales
$270,000.00
Book Value
$2.41 per share

Miscellaneous

Free Float
26,448,000
Market Cap
$59.23 million
Optionable
Not Optionable
Beta
0.29
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Ms. Evguenia Lindgardt M.B.A. (Age 49)
    Interim President, CEO & Director
    Comp: $37.5k
  • Dr. Gregory C. Critchfield M.D. (Age 70)
    M.S., Executive Director
    Comp: $790.74k
  • Dr. Steven W. Graves
    Co-Founder and Co-Chairman of The Scientific Advisory Board
  • Dr. M. Sean Esplin M.D.
    Co-Founder and Co-Chairman of Scientific Advisory Board
  • Mr. Austin Aerts
    Chief Financial Officer??
  • Dr. John J. Boniface Ph.D. (Age 61)
    Chief Scientific Officer
    Comp: $386.69k
  • Mr. Robert G. Harrison (Age 57)
    Chief Information Officer
    Comp: $384.18k
  • Mr. Benjamin G. Jackson J.D. (Age 44)
    General Counsel
    Comp: $410.75k
  • Dr. Paul Kearney Ph.D. (Age 55)
    Chief Data Officer














SERA Stock Analysis - Frequently Asked Questions

Should I buy or sell Sera Prognostics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sera Prognostics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SERA shares.
View SERA analyst ratings
or view top-rated stocks.

What is Sera Prognostics' stock price target for 2024?

2 brokers have issued 12-month price targets for Sera Prognostics' stock. Their SERA share price targets range from $2.75 to $2.75. On average, they predict the company's stock price to reach $2.75 in the next twelve months. This suggests a possible upside of 45.5% from the stock's current price.
View analysts price targets for SERA
or view top-rated stocks among Wall Street analysts.

How have SERA shares performed in 2023?

Sera Prognostics' stock was trading at $1.26 at the beginning of 2023. Since then, SERA shares have increased by 50.0% and is now trading at $1.89.
View the best growth stocks for 2023 here
.

When is Sera Prognostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our SERA earnings forecast
.

How were Sera Prognostics' earnings last quarter?

Sera Prognostics, Inc. (NASDAQ:SERA) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.17. The company earned $0.02 million during the quarter, compared to analyst estimates of $0.08 million. Sera Prognostics had a negative trailing twelve-month return on equity of 44.04% and a negative net margin of 11,534.24%.

When did Sera Prognostics IPO?

(SERA) raised $75 million in an IPO on Thursday, July 15th 2021. The company issued 4,687,500 shares at a price of $15.00-$17.00 per share.

Who are Sera Prognostics' major shareholders?

Sera Prognostics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sanders Morris Harris LLC (1.42%) and Sanders Morris Harris LLC (1.42%). Insiders that own company stock include Benjamin Jackson, John J Boniface and Robert Gardner Harrison.
View institutional ownership trends
.

How do I buy shares of Sera Prognostics?

Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SERA) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -